Somatic mutation analysis of known oncogenes, such as epidermal growth factor receptor (EGFR), has become a routine clinical test in NSCLC for patient prognosis and targeted drug selection [10]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.